Antiseptic and analgesic therapeutic agent in form of gel for processing and lubricating catheters used in examining and treating urogenital system
SUBSTANCE: therapeutic agent contains hypromellose, boric acid and a consistency base; it additionally contains anesthesin or lidocaine as an analgesic in an amount of 0.00001-0.5 g.
EFFECT: fixing a lubricating agent on the catheter enabling preventing mucosal injuries accompanying a drainage procedure, and eliminating side effects.
3 cl, 6 ex
The invention relates to medicine, namely to medicines in the form of a gel for processing and lubrication of the catheter during the examination and treatment of the urogenital system.
The catheter is a common medical instrument representing a hollow tube that serves to compose the natural channels of the body cavities, blood vessels with the external environment with the purpose of emptying, the introduction of a fluid, lavage, or conduction through them surgical instruments. Are various modifications of the elastic urethral catheters. Holding the catheter through the urethra into the bladder is always associated with some risk of damage to the mucosa of the urinary tract. Traumatic when conducting drainage in the male the urethra due to the high risk of penile injuries and bulbosus part of the urethra due to the specific structure of the wall of the urethra and its anatomical curves. Significantly reduces the risk of such complications, the use of special lubrication to reduce friction when carrying out drainage through the urethra through the creation of a sufficient layer film of lubricant between them.
Known application in our country as lubricants for catheterization of sterile liquid paraffin (mineral oil) because of its low cost and wide availability. In some cases the known lubricants - liniment of syntomycin, metiluratsilovoy ointment and levomicol.
It is widely known use as lubricants for intermittent catheterization sterile glycerol, vaseline oil or sunflower oil.
General shortcomings described above and others known and used in modern medicine lubricants for catheterization is the fact that they are not evenly grease the surface of the mucous membrane of the urethra, causing adverse reactions (allergies),and applied to the catheter is not fixed on it, and therefore erased from the catheter and remain in the external part of the urethra.
The objective of the invention is the creation of antiseptic and analgesic drugs in the form of a gel for processing and lubrication of the catheter during the examination and treatment of the urogenital system, providing a painless process of drainage and uniform coating on the catheter.
The technical result, which directed the establishment of this invention is durable fixation of lubricant on the catheter, allowing the carrying out of drainage to prevent injury to the mucous membrane, and also to eliminate adverse reactions (allergies).
This technical result is achieved by the fact that antiseptic and analgesic l the drug means in the form of a gel for processing and lubrication of the catheter during the examination and treatment of the urogenital system according to the invention contains hypromellose, boric acid and consistantness the basis of the following ratio of components in g per 1 ml of a mixture of:
|hypromellose||within 0.00001 to 0.5|
|boric acid||within 0.00001 to 0.5|
In addition, the drug contains benzocaine or lidocaine as an anesthetic in the amount within 0.00001 to 0.5,
As well as pharmaceutically acceptable bases contains macrogol 400, or macrogol 1500, or macrogol 4000.
Spent an analysis of the prior art, including searching by the patent and scientific and technical information sources, and identify sources that contain information about the equivalents of the claimed medicinal product, has allowed to establish that the petitioners have not found a similar, characterized by signs, identical to all the essential features of the claimed means.
The definition from the list of identified analogues revealed a set of essential in relation to perceived technical result of the distinctive features in the claimed medicinal product set forth in the claims.
Therefore, the claimed Le is arctonoe tool meets the criterion of “novelty.”
For verification of the compliance of medicines prior art, the applicants conducted an additional search of the known solutions, in order to identify the signs consistent with the known characteristics of the claimed invention.
The search results showed that the claimed invention not apparent to the expert in the obvious way from the prior art, certain applicants have identified no impact envisaged the essential features of the claimed medicinal product transformations to achieve a technical result.
Therefore, the claimed invention meets the criterion of “inventive step”.
The criteria of the invention “industrial applicability” is confirmed by the fact that the claimed medicinal product provides painless process of drainage and uniform coating of the lubricant on the catheter, and durable fixation of lubricant on the catheter, allowing the carrying out of drainage to prevent injury to the mucous membrane, and also to eliminate adverse reactions (allergies).
The present invention is illustrated with specific examples of implementation, which, however, are not only possible, but clearly demonstrate the possibility of achieving the desired technical result.
Example 1. To get the drug what about the funds in the form of gel mix hypromellose, boric acid and macrogol 400 in the following ratio of components in g per 1 ml of a mixture of:
|macrogol 400||the rest is up to 1 ml|
Example 2. Carried out analogously to example 1. Except that the drugs are additionally contains benzocaine in number within 0.00001-0.5 g and macrogol 1500.
Example 3. Carried out analogously to example 1. Except that it additionally contains lidocaine in number within 0.00001-0.5 g and macrogol 4000.
Example 4. Patient G., 62, entered MBUS GKB №18, Ufa with a diagnosis of burn IIIB-IV degree torso 9%. After operations how agressively to debride and autodermoplastiki on the 6th day of receipt after 6 hours are diagnosed with acute urinary retention. The bladder is palpated, marked N. Prairie, the upper pole is located 2-3 cm below the navel. Decided to catheterization of the bladder soft Foley catheter. After pre-processing the head of the penis with antiseptic solution and lubrication of the catheter of the medicinal product in example 1 was released 900 ml light yellow urine without impurities and traces of blood. After the procedure, the catheter is removed. Infection and complications, as well as complaints from the patient was not.
Example 5. Patient K., 23 years enrolled in BUS GKB №18, Ufa with a diagnosis of burn II-IIIAB-IV degree torso, the right lower limb 22% (19%). Shock severe. Upon receipt produced catheterization of the right subclavian vein, installed nasogastric gastric tube and soft Foley catheter. Within three days the urine was carried out by the catheter. After the stabilization and normalization of hemodynamics and transfer for treatment on fluidizers installation of SAT-1 has changed the urinary catheter. Pre catheters were treated with the medication in the form of a gel according to example 2.
Infection and complications, as well as complaints from the patient was not. Clinic ordinary postcatheterization urethritis was not determined. In the analysis of urine after removal of the catheter blood was not determined.
Example 6. Patient Y., 76 years old, he enrolled in BUS GKB №18, Ufa with diagnose is: burn II-IIIA degree torso, the perineum, thighs 8%. Injury in the home, hot water. When entering the field of burns moderate swelling, detachment of the epidermis, vesicles with serous clear content. On the second day after injury showed a pronounced swelling of the penis and scrotum. The patient began to Lodge complaints during urination. for planned surgical treatment regarding post-burn scar contractures of the right shoulder joint. After the surgery, on the second day appeared fever up to 38°C. Complaints of General malaise, weakness, pain in the surgical wound. Later hyperemia in the crotch area, itching and burning during urination.
Decided to catheterization of the bladder soft Foley catheter. After pre-processing the head of the penis with antiseptic solution and lubrication of the catheter of the medicinal product in the form of a gel according to example 3. Released 700 ml light yellow light of urine without impurities and traces of blood. After the procedure, the catheter is removed.
In subsequent repeated urinary retention after 6 hours, it was decided to perform catheterization of the bladder of the patient constantly. After pre-processing the head of the penis with antiseptic solution and lubrication of the catheter of the medicinal product in the form of a gel according to example 2. In the process of the treatment and care of urinary catheter treatment of the glans penis and distal part of the catheter was performed by gel. When testing urine signs of damage to the urethra is not defined. On the 14th day after the injury marked the process of epithelialization of burn wounds, reducing swelling, reducing the signs of inflammation, removal of the catheter. After restoration of spontaneous urination no complaints and infection. Abnormal discharge from the urethra was not.
The patient was discharged on the 21st day in a satisfactory condition.
Thus, the claimed antiseptic and analgesic drug in the form of a gel for processing and lubrication of the catheter during the examination and treatment of the urogenital system is a highly effective tool that provides a painless process of drainage and uniform coating of the lubricant on the catheter, and durable fixation of lubricant on the catheter, allowing the carrying out of drainage to prevent injury to the mucous membrane, and also to eliminate adverse reactions (allergies).
1. Antiseptic drug in the form of a gel for processing and lubrication of the catheter during the examination and treatment of the urogenital system, characterized in that it contains hypromellose, boric acid and consistantness the basis of the following ratio of components in g per 1 ml of a mixture of:
|hypromellose||within 0.00001 to 0.5|
|boric acid||within 0.00001 to 0.5|
2. Antiseptic drug under item 1, characterized in that it further includes benzocaine or lidocaine as an anesthetic in the amount within 0.00001 to 0.5,
3. Antiseptic drug on PP. 1-2, characterized in that as consistentarea framework contains macrogol 400, or macrogol 1500, or macrogol 4000.
FIELD: veterinary medicine.
SUBSTANCE: preparation for treatment of infected wounds in the toe region of animals, containing dimethyl sulphoxide, methyl cellulose, additionally comprises tylosin tartrate, sulphadimine, trimethoprim in the following ratio of components, wt %: tylosin tartrate - 2-3, sulphadimine - 4-5, trimethoprim - 1-1.5, dimethyl sulphoxide - 10-15, methylcellulose - 3.0-3.5, water - the rest. The claimed method comprises applying the claimed preparation without preliminary wound cleaning. The preparation is applied to the wound with the layer thickness of 2-3 mm, without application of soft dressing. The treated animals are kept for 2-3 hours on the dry surface.
EFFECT: use of claimed group of inventions increases the efficiency of treatment.
4 cl, 7 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition for treating gastroduodenal ulcer in the form of tablets, capsules or gel, containing therapeutic agents and a consistency base applicable for each dosage, wherein the therapeutic agents are as follows: recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; antiseptics; amino acids specified in a group: arginine, histidine, lysine, cysteine, methionine, glutamic acid; and antioxidants specified in a group: beta-carotene, vitamin C, vitamin E.
EFFECT: invention has the integrated body effect promoting faster healing of the mucosal defect accompanying the aggravated gastroduodenal ulcer and preventing recurrences, including by the eradication effect.
6 cl, 5 ex
FIELD: veterinary medicine.
SUBSTANCE: pharmaceutical composition in the form of ointments for treatment of mastitis in cows comprises n-tetradecyltributylphosphonium bromide as active ingredient and petrolatum as an excipient at the ratio of 1:2000.
EFFECT: invention provides a pharmaceutical composition in the form of an ointment, which is new in mechanism of action, effective when applied topically at low therapeutic concentration.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition in the form of tablets for oromucosal administration in treating infectious-inflammatory oropharyngeal diseases. The composition contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; amino acid specified in a group: arginine, histidine, glycine, glutathione, lysine, methionine, cysteine; an antiseptic, a preserving agent, flavours specified in a group: tea tree oil, eucalyptus leaf oil, mint leaf oil and a consistence base.
EFFECT: invention makes the composition applicable in fragile and frequently ill patients for reducing a disease recurrence.
7 cl, 1 ex
SUBSTANCE: pathogenetic treatment of chronic tonsillitis and/or hypertrophy of palatine tonsils in preschool children suffering from lymphoproliferative syndrome is ensured by the palatine tonsils debridement. An interleukin-1β(IL-1β) level is measured in the palatine tonsils washing. If the measured value is less than 5.8 pg/ml, recombinant interleukin-1β (IL-1β) is to be administered orally by phonophoresis with the use of the Tonsillor MM apparatus. Two courses of 10 procedures every 14 days are performed. The clinical effectiveness is assessed if observing a positive dynamics of IL-1β measured in the palatine tonsils washing 17 and 41 days after the beginning of the immunomodulatory therapy.
EFFECT: higher clinical effectiveness ensured by the differentiated selection of children for carrying out the immunomodulatory therapy, reducing a rate of infectious involvements of the palatine tonsils in the declared group of patients by the pathogenetically reasoned application of recombinant IL-1β.
3 cl, 2 tbl, 1 ex
SUBSTANCE: present invention refers to medicine. The preparation contains the active substance furacilin (nitrofural, 2-[(5-nitro-2-furanyl)methylen]hydrazine carboxamide), the excipient - sodium chloride, a gas-forming mixture, an acidity regulator for reducing pH from 6.5 to 7.5 and a lubricant if needed. The gas-forming mixture consists of an organic acid and sodium hydrocarbonate. According to the method for preparing effervescent tablets of furacilin, furacilin and sodium chloride are milled in a combination; all the ingredients are placed into a mixer, and the prepared mixture is tabletted by direct compression. The antimicrobial therapeutic preparation of furacilin in the form of effervescent tablets is used for septic wounds, bed sores, small skin damages, including scratch marks, abrasions, cuts; infectious-inflammatory oral and throat diseases, including acute tonsillitis, stomatitis, gingivitis and tonsillitis. The effervescent tablets of furacilin are storage-stable for two years and water-soluble at room temperature for 5 minutes.
EFFECT: preparing the antimicrobial therapeutic preparation in the form of the effervescent tablets used for preparing the solution for local and external application.
4 cl, 6 tbl, 3 ex
SUBSTANCE: biologically active additive Laviocard+ is prescribed orally 1 capsule 2 times a day with food for 21 days. That is combined with daily wound irrigations with neutral analyte of anhydrohexitol nucleic acid with leaving a sterile gauze bandage impregnated with neutral analyte of anhydrohexitol nucleic acid in the wound until it is clean. That is followed by daily bandaging with Lavitol cosmetic dihydroquercetin powder applied on the wound surface 1-2 mm thick until the wound is healed.
EFFECT: reduced length of wound healing by stimulating the regeneration processes in tissues.
1 ex, 3 tbl
SUBSTANCE: inorganic clay, represented by sodium-calcium, and/or calcium and/or ferrous forms of montmorillonite, is modified with a water solution of silver nitrate with a concentration 0.16-9.9 wt % in a weight ratio clay:water solution of silver nitrate 1:5. Modification is carried out with mixing from 3 to 7 hours at a temperature in the interval from 10°C to the temperature of boiling. The obtained material is washed with distilled water to pH ≈6-5, until excess of silver nitrate is removed, stood at room temperature and decanted. The material is dried at a temperature of 20-160°C.
EFFECT: obtaining an efficient antibacterial material for traditional and veterinary medicine.
2 tbl, 5 ex
FIELD: veterinary medicine.
SUBSTANCE: agent for prevention of mastitis in dairy cows in the dry period, characterised in that it contains as ingredients the polymer PVP/VA, silicone, polyhexamethylene biguanide, ethyl alcohol, glycerol - as emollient component, gelation agents - triethanolamine and carbopol and purified water in the following ratio of ingredients, %: polymer PVP/VA 9-10; silicone 5-6; ethyl alcohol 35-40; polyhexamethylene biguanide 0.008-0.01; glycerol 5; gelation agents - triethanolamine and carbopol 0.1; purified water - the rest.
EFFECT: method enables to minimise or eliminate the use of chemotherapeutic agents, antibiotics and their derivatives, sulphonamides, nitrofurans and eliminate the side effect of the agent on animal body, as well as to reduce the number of visits of the veterinarian during the dry period of cows, to improve the preventive efficacy.
1 tbl, 3 ex
SUBSTANCE: invention refers to the veterinary science, particularly to substances used in treating purulent-necrotic involvements of bovine's distal extremities, including digital dermatitis. A preparation for treating bovine digital dermatitis in the form of an ointment consists of an excipient, containing an ointment base, and an active ingredient - zinc oxide and copper sulphate in the following proportions, wt %: zinc oxide 9-11, copper sulphate 35-45, the ointment base - the rest.
EFFECT: invention provides higher clinical effectiveness with cost cutting for the ointment preparation.
SUBSTANCE: anterior chamber anaesthesia and pupil dilatation accompanying anterior eye segment surgeries experimentally involve a preoperative administration of a composition in an amount of 0.1-0.2 ml representing 0.005% 1-(3-pyrrolidinopropyl)-2-phenylimidazo[1,2-a]benzimidazole dihydrochloride into the anterior eye segment. The composition is prepared in 1% viscoelastic solution, visiton PEG.
EFFECT: prolonging anaesthetic effect and pupil dilatation with no mydriatics used.
FIELD: veterinary medicine.
SUBSTANCE: intramesovarian blockade of ovarian and cranial uterine nerves is carried out by laparotomy and administration in the mesovarium of 0.5-1% solution of novocaine or lidocaine. Blockade is carried out by inserting the needle of the syringe into the mesovarium in the vicinity of the ovarian bursa and uterine horn at an acute angle to the surface of the ovarian mesenterium to a depth of 3-4 cm. At that 3 ml of anaesthetic is administered to small breeds of dogs and fur-bearing animals, and from 3 to 9 ml of anaesthetic is administered to large and giant breeds of dogs as from one and from the opposite side of the body.
EFFECT: effective implementation of intramesovarian blockade by taking into account the anatomical and the breed features of the animal category.
SUBSTANCE: patient is laid on his/her side opposite a block region. A guide mark is a vertical line in a projection of Petit's triangle from the twelfth rib to a wing of ilium. A needle is pricked into the skin on the vertical line at 1.5-2.5cm above the wing of ilium. 0.25% Novocaine is administered in layers into the skin and subcutaneous fat. The needle is advanced into the lumbar region from back to front in the medial direction along the lateral edge of broadest muscle of back at 6-8cm. Novocaine 120ml is administered into the lower order of the lumboiliac fossa formed in this region.
EFFECT: effective and safe pain management in the given category of patients by providing the required Novocaine concentration in the retroperitoneal space.
1 dwg, 1 ex
SUBSTANCE: aqueous composition for anaesthesia is proposed, which comprises propofol as an active agent, the PEG-660-12-hydroxystearate as a solubiliser, benzyl alcohol, or chloroethanol or parabens as preservative, the tocopherol and arginine or glycine at a specific content of components wt %. The GABA agonists can be additionally added to the composition, e.g. aminophenyl-butyric acid, local anesthetics such as lidocaine, alpha-2-adrenoceptor agonists such as xylazine. The method is proposed for implementing anaesthesia comprising administering to a patient of an effective amount of the claimed composition.
EFFECT: invention provides low toxicity of dosage form and high efficiency.
5 cl, 3 tbl, 1 ex
SUBSTANCE: radionuclide indicator is administered to record the dynamics of its distribution in limb tissues by a radionuclide method. The examination is performed at rest and during a load test. The load test represents an epidural block by gradual administration of bupivacaine 25-30 mg between L2-L3 vertebrae for 5-7 minutes. That is followed by measuring a blood flow as a percentage of its value to the same level in an analogous segment of a collateral limb.
EFFECT: qualitative assessment of the circulation reserve in various categories of patients, including disabled ones by inhibiting sympathetic and minimally sensory activity with maintaining the patients' motor activity.
2 dwg, 2 ex
SUBSTANCE: invention refers to medicine, namely to abdominal surgery and anaesthesiology, and can be used where it is necessary to anaesthetise after the prosthetic hernioplasty for median postoperative ventral hernias. That is ensured by placing an endoprosthesis under the aponeurosis, a polyvinylchloride catheter is placed into the formed spaced around the periphery of a postoperative wound in the form of an oval above the endoprosthesis plane at 2.5-3 cm from its edges. Along its full length, the catheter has multiple side holes. Single openings are created in a projection of a lower corner of the wound, and the catheter ends are brought out onto the skin. An inlet of the catheter is attached to a local anaesthetic dosage device by means of a cannula. That is followed by a controlled prolonged irrigation with 2.5% Ropivacaine 20 ml every 6-8 hours during 2-3 days.
EFFECT: method enables the adequate postoperative anaesthesia, as well as the length of the postoperative intestinal distention by providing the uniform controlled administration of the local anaesthesia solution.
7 dwg, 1 ex
SUBSTANCE: invention relates to medicine, namely to anaesthesiology and surgery, and can be used in case of anaesthesia necessity in patients after herniorrhaphy with inguinal access in case of inguinal hernias. For this purpose after the main stage of operation - hernioplasty, before suturing of the aponeurosis of the external oblique abdominal muscle, through subcutaneous adipose cellular tissue a puncture of 1 cm more medially and 1 cm higher than the anterior-superior iliac spine is made. A multiperforated catheter is introduced through the puncture under finger and visual control in such a way that its distal end is near the pubic tubercle. The catheter is placed under the aponeurosis of the external oblique abdominal muscle in the inguinal canal above and parallel to the spermatic cord in men or the round ligament of uterus in women. All the side holes of the catheter must be located in the subaponeurotic space. The first 48 hours of the post-operation period the local anaesthetic is continuously introduced by drop infusion at a rate of 2-4 ml/h or by bolus introduction in a dose of 10 ml each 4-6 hours through the catheter. After 48 hours the catheter is removed.
EFFECT: method provides adequate anaesthesia in the said category of patients in the post-operation period without application of additional anaesthetic preparations due to blockade of ilioinguinal, ilioceliac and hollow branch of genitofemoral nerves.
2 dwg, 2 ex
SUBSTANCE: group of inventions refers to medicine, and may be used in treating the patients suffering headaches and facial pains. There are presented versions of a drug delivery device comprising an injector a first end of which is left outside patient's nasal passages. Another end of the injector comprises one or more holes for spraying a drug upwards, and/or to the side, and/or to the front towards a sphenopalatine ganglion, an input device interacting with a patient's nostril and comprising a canal for receiving the injector. Additionally, the device can comprise a handle connected to the input device and provided for receiving the canal of the input device. The injector can move between a storage position before the interaction, and an interaction position related to the interaction. There are also presented versions of the method of using the above device that involve introducing the injector through the nasal passage into median and/or posterior and/or inferior region in relation to the patient's sphenopalatine ganglion, and spraying the drug.
EFFECT: group of inventions provides faster and more effective headache and facial pain relief by safe and accurate drug delivery of the therapeutic substances blocking the sphenopalatine ganglion.
49 cl, 4 dwg, 30 ex
SUBSTANCE: invention relates to a novel biologically active 2,6-dimethylanilide of N-cyclohexylpyrrolidine-2-carboxylic acid, having surface, infiltration and conduction anaesthesia activity, considerably better than bupivacaine and ropivacaine with the same or less toxicity.
EFFECT: improved compounds.
FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is a pharmaceutical composition in the form of a spray for treating a damage by non-lethal irritants (e.g. pelargonic acid morpholide), containing pediphene in the following proportions, wt/volume %: pediphene hydrochloride 0.01-10.0; sodium chloride 0.1-10.0; water for injections up to 100 ml. What is shown is the efficacy of pediphene in compliance with the declared application ensured by the local anaesthetic effect of the drugs.
EFFECT: drug preparation has no allergenic and immunotoxic properties.
3 dwg, 40 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, particularly to pharmaceutical industry, and describes a dosage form of Clopidogrel presented in the form of a solid gelatine capsule. The dosage form contains Clopidogrel hydrogen sulphate, lactose anhydride, microcrystalline cellulose, sodium croscarmellose, colloidal silicon dioxide and magnesium stearate.
EFFECT: according to the invention, the dosage form of Clopidogrel contains a high amount of the active ingredient; it is prepared without the use of a wet granulation technique, and provides the more accurate dosage of the ingredients and the stability of the substances used.